

18th Annual Indy Hematology Review™

Saturday, August 21, 2021

The Westin Indianapolis
241 W. Washington St.
Indianapolis, IN 46204

Registration Brochure

Organized by:
Indy Hematology Education, Inc.



Achieving tomorrow's outcomes through education today.™

Presented by:



Community

Health Network

in collaboration with

**MDAnderson
Cancer Network®**

A program of MD Anderson Cancer Center

Purdue University College of Pharmacy designates this live activity for a maximum of 8.75 AMA PRA Category 1 Credit(s)™. Symposium – 8:30 am - 6:50 pm. Purdue University College of Pharmacy designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credit(s)™ (Town Hall Interactive Meeting – 7:00 pm - 8:30 pm).

Plan to participate from 8:30 am – 8:30 pm and earn the full 10.25 AMA PRA Category 1 Credit(s)™

LIVE and VIRTUAL Registration Options

In today's climate it is difficult to pass up a LIVE meeting that offers the opportunity to network with hematology thought leaders and over 400 hematology professionals from across the country. Our goal at this year's Review is to present the most important data presented at ASH, and data from other major hematology and oncology conferences of the past year, including the American Society of Clinical Oncology and the European Hematology Association Congress.

The Indy Hematology Review™ brings together over 400 hematologists, oncologists, radiologists, physician assistants, oncology RN's, nurse practitioners, pharmacists, medical students, and other allied health professionals to examine significant scientific updates in clinical hematologic research. Learn how these updates directly affect the study and practice of hematology and discover how new research can be translated into new patient care strategies.



Participating in the Symposium will affect competence, performance, and patient outcomes in a variety of ways:

1. Attendees will be able to implement the most clinically effective management strategies for the various types and stages of lymphoma, leukemia, and multiple myeloma to improve patient care.
2. Attendees will know and understand how to apply updated research in the diagnosis and treatment of Waldenström's Macroglobulinemia.
3. Attendees will know the new advancements in immune check point inhibitors within hematologic malignancies and use case reports and summary information to update their knowledge in hematologic malignancies.
4. Attendees will have knowledge of new treatment regimens for Hematopoietic Stem Cell transplant and know when to apply relevant treatment and when to avoid.
5. Attendees will know up to date research information on benign hematology.
6. Attendees will be updated on new management strategies in follicular lymphoma, with updated first line, second line, and maintenance treatment options.

Visit the Exhibit Hall

Visit the exhibit hall to experience the latest technology, services, devices, and research in hematology. The exhibit hall offers an opportunity to learn about a wide range of products and services offered by pharmaceutical companies, medical suppliers, biotechnology companies, healthcare systems, and research-based companies. Stop in for a beverage and snack at the "Physicians' Lounge" as you visit exhibitors.



Register online: www.indyhematologyreview.com

SUPPORTERS & SPONSORSHIPS



Achieving tomorrow's outcomes through education today.™



Community
Health Network

in collaboration with

MDAnderson
CancerNetwork

A program of MD Anderson Cancer Center

The 2021 Indy Hematology Review is supported by the following companies as of 4/14/21:

AbbVie Oncology	Jazz Pharmaceuticals
Acceleron	Oncocept
Alexion Pharmaceuticals	Pharmacyclics
AstraZeneca	Rigel Pharmaceuticals
BeiGene	Sanofi Genzyme
GlaxoSmithKline	Takeda Pharmaceutical
Incyte	

INDY HEMATOLOGY EDUCATION, INC.



Achieving tomorrow's outcomes through education today.™

Indy Hematology Education, Inc. is a 501(c), non-profit corporation, incorporated on February 15, 2010, in the State of Indiana, with the following purposes:

- (a) Raise awareness and provide education regarding hematology and oncology diseases and disorders
- (b) To encourage youth to pursue careers in hematology and oncology and
- (c) To connect individuals suffering from or affected by hematology and oncology diseases and disorders to organizations, programs, and service providers.

PLANNING COMMITTEE

Ruemu E. Birhiray, MD (Chair)

CEO, Indy Hematology Education, Inc.
Partner, Hematology Oncology of Indiana, a Division of American Oncology Network

Michael C. Wiemann, MD, FACP (Co-Chair)

Vice President, Indy Hematology Education, Inc.
Providence Hospital/St. John Health, Senior VP, CMO

Donna Birhiray, OTR, MBA

COO, Indy Hematology Education, Inc.
Treasurer

Thalia Hammond

Indy Hematology Education, Inc.
Director of Conventions

Jennifer Wheeler-Terry, JD

Wabash College
Secretary

Debbie Locklear

Meeting Services Unlimited, Inc.
President

Tina Machina, CMP

Meeting Services Unlimited, Inc.
Director of Conventions

BOARD OF DIRECTORS

Ruemu E. Birhiray, MD, CEO and President

Michael C. Wiemann, MD, FACP, Vice President

Donna M. Birhiray, OT, MBA, COO and Treasurer

Jennifer Terry, JD, Secretary

Thalia Hammond, Director of Conventions



Register online: www.indyhematologyreview.com

SYMPOSIUM AGENDA

7:00 AM – 2:30 PM – Registration

7:00 AM – 4:45 PM – Exhibit displays

7:30 AM – Breakfast Product Theaters

8:30 AM – State of the Art: 2021 Emerging Therapies in Hematologic Malignancies

Ruemu E. Birhiray, MD – Chair
CEO and President, Indy Hematology Education, Inc., Partner, Hematology Oncology of Indiana, a Division of American Oncology Network, PC, Clinical Professor, Marian University College of Osteopathic Medicine (Indianapolis, IN)

9:00 AM – Multiple Myeloma: The Cure Around the Corner

Kenneth Anderson, MD
Kraft Family Professor of Medicine, Harvard Medical School, Director of the LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute (Boston, MA)

9:30 AM – Waldenström's Macroglobulinemia: Targeting for the BIG Kill

Steven Treon, MD, MA, PhD, FACP, FRCP
Director of the Bing Center for Waldenstrom's Macroglobulinemia, Dana-Farber Cancer Institute Professor of Medicine at Harvard Medical School, Chair, WM Clinical Trials Group (Boston, MA)

10:00 AM – Chronic Myeloid Leukemia: Therapy Updated and Modified for 2021

Richard Larson, MD
Professor of Medicine in Hematology/Oncology, Director of Hematologic Malignancies Clinical Research Program The University of Chicago Comprehensive Cancer Center (Chicago, IL)

10:30 AM – Break with Q & A

10:45 AM – Indolent and Mantle Cell Lymphoma: Updating the Toolbox, Including and Beyond Anti-CD20 Antibodies

Sonali Smith, MD
Elwood V. Jensen Professor of Medicine, Interim Section Chief of Hematology/Oncology, and Director

of the Lymphoma Program at the University of Chicago's Department of Medicine (Chicago, IL)

11:15 AM – Aggressive B and T Cell Lymphomas: Emerging Therapies

John Leonard, MD
Richard T. Silver Distinguished Professor of Hematology and Medical Oncology, Senior Associate Dean for Innovation and Initiatives, Weill Cornell Medicine, Attending Physician, New York-Presbyterian Hospital (New York, NY)

11:45 AM – Acute Lymphoblastic Leukemia: Biologic and Targeted Therapy

Hagop Kantarjian, MD
Professor and Chair, Department of Leukemia, University of Texas, MD Anderson Cancer Center Samsung Distinguished Leukemia Chair, Cancer Medicine, Special Fellow in Health Policy, Rice University Baker Institute (Houston, TX)

12:15 PM – Benign Hematology: Clotting, Bleeding and More

Craig Kessler, MD
Professor of Medicine and Pathology, Attending Physician, Division of Hematology-Oncology, Georgetown University Medical Center, Director, Division of Coagulation, Department of Laboratory Medicine and Director of the Therapeutic and Cellular Apheresis Unit. (Washington, DC)

12:45 PM – Q & A

1:00 PM – Lunch Product Theaters

2:00 PM – T. HOWARD LEE KEYNOTE LECTURE: State of the Art: Current and Emerging Treatment of Hodgkin's Lymphoma

Ranjana Advani, MD
Saul A. Rosenberg Professor of Lymphoma, Stanford University School of Medicine (Stanford, CA)

3:00 PM – Challenging Cases Presentation

Michael Wiemann, MD, FACP – Co-Chair
President of the Ascension Medical Group, Michigan, Clinical Professor of Medicine at Michigan State University College of Human Medicine (Warren, MI)

3:25 PM – Chronic Lymphocytic Leukemia: Curability and Duration of Therapy

Steven Coutre, MD
Professor of Medicine, Division of Hematology, Stanford University School of Medicine (Palo Alto, CA)

3:55 PM – Myeloproliferative Neoplasms: Risk Stratification and Therapy; A 2021 Global Perceptive

Ruben Mesa, MD, FACP
Executive Director of the Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center (Boerne, TX)

4:25 PM – Break with Q & A

4:40 PM – Mastocytosis and Eosinophilia: The Vexing Disorders of the Blood

Ayalew Tefferi, MD
(Rochester, MN)

5:10 PM – Acute Myeloid Leukemia: Finally, A Trip Beyond 7+3

Harry Erba, MD, PhD
Professor of Medicine, Division of Hematologic Malignancies and Cellular Therapy Director, Duke Leukemia Program, Chair, SWOG Leukemia Committee, Duke University (Durham, NC)

5:40 PM – Myelodysplastic Syndrome: Emerging and Targeted Therapies

Richard Stone, MD
Chief of Staff and Director of Translational Research, Adult Leukemia Program, Professor of Medicine, Harvard Medical School
Dana-Farber Cancer Institute (Boston, MA)

6:10 PM – Hematopoietic Stem Cell Transplantation: Updating the Old Closet

Richard Childs, MD
Clinical Director, National Heart, Lung, and Blood Institute, National Institutes of Health (Bethesda, MD)



6:40 PM – Break

7:00 PM - Town Hall Reception

7:00 PM – 8:30 PM – Hematologic Malignancies

Town Hall

Ruemu Birhiray, MD - Moderator

Steven Coutre, MD

Sonali Smith, MD

Morie Gertz, MD, MACP

Roland Seidler Jr. Professor of the Art of Medicine and Chair Emeritus of the Department of Internal Medicine, at Mayo Clinic (Rochester, MN)

Jessica Altman, MD

Professor in the Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine Director, Acute Leukemia Program, Robert H. Lurie Cancer Center, Northwestern University (Chicago, IL)

Jennifer Woyach, MD

Professor, Division of Hematology, Section Chair of Chronic Lymphocytic Leukemia (CLL), Physician Scientist, Ohio State University (Columbus, OH)

Irene Ghobrial, MD

Professor, Dana-Farber Cancer Institute, Harvard Medical School, Director of the Clinical Investigator Research Program, Dana-Farber Cancer Institute, Co-Director, Center for Prevention of Progression, Co-Leader, Blood Cancer Research Partnership, Director, Michele & Stephen Kirsch Laboratory. (Boston, MA)

Charles Schiffer, MD

Professor of Medicine and Oncology, Joseph Dresner Chair, Hematologic Malignancies, Wayne State University School of Medicine and Karmanos Cancer Institute (Detroit, MI)

NURSING AND ALLIED PROVIDERS SYMPOSIUM AGENDA

MODERATOR: Thalia Hammond

8:30 AM – State of the Art: 2021 Emerging Therapies in Hematologic Malignancies

Ruemu E. Birhiray, MD – Chair

9:00 AM – Management of Long-Term Survivors of Hematologic Malignancies

Kristi Orbaugh, RN, MSN, RNP, AOCN

Adult Nurse Practitioner, Community Hospital Oncology Physicians (Indianapolis, IN)

9:30 AM – Benign Hematology and Coagulopathy

Craig Kessler, MD

10:00 AM – Break with Q & A

10:10 AM – Aggressive Lymphomas

John Leonard, MD

10:40 AM – Chronic Lymphocytic Leukemia

Steven Coutre, MD

11:10 AM – Break with Q & A

11:20 AM – Myeloproliferative Neoplasms

Rubin Mesa, MD, FACP

11:45 AM – Indolent Lymphomas and Hodgkin's Lymphoma

Sonali Smith, MD

12:10 PM – Recognizing Toxicities of Oral Oncolytics in the Management of Hematologic Malignancies

David Reeves, PharmD, BCOP

Associate Professor of Pharmacy Practice, College of Pharmacy and Health Sciences, Butler University
Clinical Pharmacy Specialist in Hematology/Oncology, Franciscan Physician Network
Oncology/Hematology Specialist (Indianapolis, IN)

12:35 PM – Multiple Myeloma and Waldenström's


Irene Ghobrial, MD

12:55 PM – Break with Q & A

1:00 PM – Lunch: Product Theaters

2:00 PM – Join General Session for the remainder of the Symposium

Disclosure information, biographies, and slides (where authorized by the presenter) will be available at indyhematologyreview.com





REGISTRATION

Register for the LIVE participation or the VIRTUAL participation. [Click here to Register](#)

Early Bird Registration: ends July 27, 2021

Early Bird Physicians	\$245.00
Early Bird Physicians - Virtual	\$345.00
Early Bird Allied Health & Nurses	\$170.00
Early Bird Allied Health & Nurses - Virtual	\$270.00
Early Bird Nurse Practitioners & Pharmacists	\$195.00
Early Bird Nurse Practitioners & Pharmacists - Virtual	\$295.00
Industry & Exhibitors	\$395.00
Industry & Exhibitors - Virtual	\$495.00
Student/Fellow Scholarship* (Limited Number)	\$50.00
Student/Fellow Scholarship* (Limited Number) - Virtual	\$75.00
Nurse Scholarship* (Limited Number)	\$50.00
Nurse Scholarship* (Limited Number) - Virtual	\$75.00

Standard Registration: after July 27, 2021

Physicians	\$295.00
Physicians - Virtual	\$395.00
Allied Health & Nurses	\$220.00
Allied Health & Nurses - Virtual	\$320.00
Nurse Practitioners & Pharmacists	\$245.00
Nurse Practitioners & Pharmacists - Virtual	\$345.00
Industry & Exhibitors	\$395.00
Industry & Exhibitors - Virtual	\$495.00
Student/Fellow Scholarship* (Limited Number)	\$50.00
Student/Fellow Scholarship* (Limited Number) - Virtual	\$75.00
Nurse Scholarship* (Limited Number)	\$50.00
Nurse Scholarship* (Limited Number) - Virtual	\$75.00

NOTE: When registering healthcare providers from your office, fill in the person's full name and email address so the post-event survey and certificate for continuing education credits are emailed directly to the registrant.

**A limited number of scholarships are available on a first-come, first-served basis, based on approval.*

Register online: www.indyhematologyreview.com



REFUND POLICY

Request a registration cancellation refund on or before July 22, 2021, to receive a Full Refund. After July 22, there is NO REFUND.

HOTEL RESERVATIONS

Make reservations online to reserve a room. You may also call The Westin Indianapolis toll free at 1-800-937-8461. Reference "Indy Hematology Review" to receive the group rate of \$162 plus tax (currently 17%). The block of discounted rooms will close on Thursday, August 5, 2021.

[Click to make reservations online.](#)

PARKING

Parking is available at The Westin Indianapolis. 24-hour parking rates are currently: \$40.00 on-site parking; \$45.00 valet (rates are subject to change without notice).

Self-parking is also available 2 blocks away, at the Government Center Washington St. Parking Facility, 401 West Washington Street. Daily Maximum currently: \$25.00 (rates are subject to change without notice).

PHOTOGRAPHY

Photos of attendees will be taken throughout the Symposium. These photos are for Indy Hematology Review and Indy Hematology Educations, Inc. use only and may appear on the IHR website, in promotional brochures, or other future promotional material. By virtue of your attendance, you agree to usage of your photograph in such media, unless we are otherwise notified in writing and receive a clear photo of you.

QUESTIONS?

Please contact 317-841-7171,
Indyhr@conventionmanagers.com.



Register online: www.indyhematologyreview.com

CONTINUING EDUCATION INFORMATION

PHYSICIANS



In order to receive CE, you must attend the entire Symposium from 8:30 am – 6:50 pm. Successful completion of this CME activity requires participants to complete a Post-Evaluation.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Learning Objectives (ACCME, ANCC, ACPE)

1. Discuss new emerging hematology therapies in general and for chronic Myeloid Leukemia, acute Promyelocytic, and Myeloproliferative neoplasms.
2. Evaluate molecular diagnosis, targeted therapies, and resistance mechanisms of Waldenström's Macroglobulinemia to assist in disease recognition.
3. Discuss the advancement of immune check point inhibitors within hematologic malignancies and updated treatment paradigms presented at the American Society of Hematology meeting, December 2020.
4. Recommend new regimens for Hematopoietic Stem Cell transplantation and identification of transplant candidates.
5. Review the advancement in hematology research and treatment of diseases of coagulopathy, compliment and cytopenia.
6. Review current and emerging treatment regimens in lymphomas.
7. Review and update advances in the treatment of disorders of compliment and aplastic anemia.
8. Present challenging clinical cases and discuss management strategies of hematologic malignancies and disorders with the application of current and emerging medical literature.

CME Accreditation Statement

This live activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy and Indy Hematology Education, Inc. Purdue University is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

Purdue University College of Pharmacy designates this live activity for a maximum of 8.75 AMA PRA Category 1 Credit(s)[™]. Symposium - 8:30 am - 6:50 pm. Purdue University College of Pharmacy designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credit(s)[™] (Town Hall Interactive Meeting - 7 - 8:30 pm). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Statement

All faculty, staff, and reviewers involved in the planning, review, or presentation of continuing education activities provided by Purdue University College of Pharmacy are required to disclose to the audience any relevant commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. All additional planning committee members, staff, and reviewers of Indy Hematology Education, Inc. and Purdue University College of Pharmacy have no relationships to disclose.

NOTE: While it offers CME credits, this activity is not intended to provide extensive training or certification in the field.

NURSES

In order to receive CE, you must attend the entire Symposium from 8:30 am – 6:50 pm. Successful completion of this CME activity requires participants to complete a Post-Evaluation.

CNE Accreditation Statement

Purdue University Continuing Nursing Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This program is approved for 8.5 contact hours (Symposium: 8:30 am - 6:50 pm).

This program is approved for 1.50 contact hours (Town Hall Interactive Meeting: 7 - 8:30 pm).

PHARMACISTS

In order to receive CE, you must attend the entire Symposium from 8:30 am – 6:50 pm. Successful completion of this CME activity requires participants to complete a Post-Evaluation.



CPE ACCREDITATION STATEMENT

Purdue University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is a knowledge based, continuing education activity of Purdue University, an equal access/equal opportunity institution.

CPE Accreditation Statement

Purdue University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is a knowledge based, continuing education activity of Purdue University, an equal access/equal opportunity institution.

Symposium: 8:30 am - 6:50 pm.

Universal Activity Number (UAN): 0018-9999-21-012-L01-P
This program is approved for 8.5 contact hours (0.85 CEU's).

Town Hall Interactive Meeting: 7 - 8:30 pm.

Universal Activity Number (UAN): 0018-9999-21-013-L01-P
This program is approved for 1.5 contact hours (0.15 CEU's).

Register online: www.indyhematologyreview.com